1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Towa Pharmaceutical Co., Ltd.

Towa Pharmaceutical Co., Ltd.

TWAPF
Towa Pharmaceutical Co., Ltd.US flagOther OTC
25.98
USD
- -
- -
1.28BMarket Cap
Towa Pharmaceutical Co., Ltd.
TWAPF
(Other OTC)

Recent

price

25.98

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
896
946.71
1,083.46
1,203.29
1,401.77
1,647.64
1,726.28
1,898.63
2,135.86
2,243.14
3,147.46
3,365.09
4,243.22
4,630.98
5,273.78
5,560.74
2,448.93
Revenue per Share
113.51
111.48
121.62
117.52
218.06
154.18
113.31
131.99
273.83
294.72
283.62
323.35
44.72
328.59
385.71
106.66
187.32
Basic EPS, GAAP
-61.34
-116.59
-39.87
-1.45
-111.19
-208.38
-222.99
78.38
155.42
294.54
43.26
173.79
-567.33
-632.13
-158.91
128.01
- -
Free Cash Flow per Basic Share
20.81
24.97
24.18
25.01
25.01
35.21
31.66
31.64
31.68
42
44.01
48.99
62.98
59.98
59.99
79.98
- -
Dividend per Share
906.07
990.35
1,090.67
1,179.66
1,373.86
1,434.79
1,522.97
1,624.07
1,864.88
2,126.68
2,369.18
2,685.15
2,781.14
3,167.24
3,486.37
3,617.93
3,232.14
Book Value per Share
894.31
975.17
1,075.61
1,161.89
1,356.92
1,411.89
1,484.48
1,584.72
1,835.01
1,811.06
2,065.16
1,505.53
1,705.52
2,139.53
2,555.16
3,076
2,269.46
Tangible Book Value per Share
52
51
51
51
51
50
49
49
49
49
49
49
49
49
49
49
49
Basic Weighted Avg Shares
46,145
48,719
55,241
61,351
71,470
82,115
84,949
93,430
105,104
110,384
154,900
165,615
208,859
227,934
259,594
273,710
120,538
Sales/Revenue/Turnover
20.92
18.69
13.98
12.56
15.54
13.56
8.09
12.46
15.19
14.62
12.86
11.6
2.64
7.74
8.95
8.44
8.83
Operating Margin (%)
1,873
2,637
4,909
5,407
5,724
7,329
7,980
8,173
8,340
8,285
10,425
10,954
19,409
17,888
20,099
22,837
- -
Depreciation Expense
5,846
5,737
6,201
5,992
11,118
7,684
5,576
6,495
13,475
14,503
13,958
15,914
2,201
16,173
18,986
5,250
9,220
Net Income, GAAP
38.04
41.05
33.39
31.14
26.88
22.41
22.95
33.95
28.65
29.97
25.47
28.46
52.2
33.88
27.89
60.11
34.46
Effective Tax Rate (%)
12.67
11.78
11.23
9.77
15.56
9.36
6.56
6.95
12.82
13.14
9.01
9.61
1.05
7.1
7.31
1.92
7.65
Profit Margin (%)
25,557
22,419
27,530
32,037
35,588
63,870
51,951
58,296
71,029
51,361
85,774
51,791
104,461
137,600
159,367
170,476
152,539
Working Capital
8,518
9,802
12,912
16,620
18,468
53,502
54,309
59,849
58,442
51,664
74,098
79,194
150,314
189,838
206,878
196,164
204,459
LT Debt
46,664
50,494
55,609
60,146
70,047
70,605
74,944
79,919
91,769
104,663
116,598
132,168
136,893
155,892
171,624
178,103
159,109
Total Equity
11.15
8.69
7.47
6.79
9.08
7.71
4.03
5.45
7.37
6.46
7.61
5.74
0.91
3.5
4.33
2.26
1.94
Return on Invested Capital (%)
11.4
9.67
9.34
7.95
12.92
7.09
4.36
4.74
8.98
8.54
7.35
6.82
0.88
5.11
5.29
1.52
2.69
Return on Capital (%)
13.2
11.81
11.69
10.35
17.08
10.93
7.66
8.39
15.7
14.77
12.62
12.79
1.64
11.05
11.59
3
6.03
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
13,470
- -
16,137
LT Borrowings
189,124
- -
198,040
LT Finance Leases
714
- -
6,419
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
49
49
49
Market Capitalization
181,510
192,935
172,298

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
217,718
- -
227,249
Cash, Cash Equivalents & STI
29,650
- -
41,268
Accounts Receivable, Net
62,916
- -
53,052
Inventories
101,072
- -
105,529
Total Current Liabilities
80,118
- -
74,710
Payables & Accruals
- -
- -
- -
ST Debt
13,470
- -
16,137
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.77%
8.93%
3.78%
Free Cash Flow
-39.57%
-73.75%
-180.55%
Net Income, GAAP
60.81%
101.54%
-72.35%
Sales/Revenue/Turnover
13.28%
12.3%
5.44%
Total Cash Common Dividend
9.47%
13.69%
33.32%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
259,594
2026
- -
- -
- -
- -
273,710
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
385.71
2026
- -
- -
- -
- -
106.66
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
59.99
2026
- -
- -
- -
- -
79.98
2027
- -
- -
- -
- -
- -
Similar Companies
Pacira BioSciences, Inc. (PCRX)
Aspen Pharmacare Holdings Limited (APNHF)
JW Pharmaceutical Corporation (001067.KS)
Alliance Pharma plc (APH.L)
Fertil-A-Chron, Inc. (FEKR)
Dawnrays Pharmaceutical (Holdings) Limited (2348.HK)
Business
Towa Pharmaceutical Co., Ltd. (TWAPF) manufactures and sells pharmaceutical products, primarily focusing on prescription and over-the-counter drugs for gastrointestinal, circulatory, and dermatological conditions; active pharmaceutical ingredients; and medical devices such as tablet presses and powder dispensers. The company offers specialized machinery including the AccuFill series for precise tablet filling and the Mini Press II for small-batch production, alongside pharmaceutical preparations like anti-ulcer agents and antihypertensives under its own brands. Towa operates primarily in Japan with international sales through subsidiaries and partners in Asia, Europe, and North America, targeting hospitals, pharmacies, and pharmaceutical manufacturers; headquartered in Tokyo, it was founded in 1966. Recent developments include the launch of new high-speed tablet compression machines and expansions in API production capacity in 2024, alongside a strategic alliance with a European medical device firm for distribution in 2025; the company also completed a minor acquisition of a regional distributor in Southeast Asia to bolster its OTC drug market presence.

Company News

Company News APIChatGPT

  • defenseworld.net

    Financial Contrast: Towa Pharmaceutical (OTCMKTS:TWAPF) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX)